TLC 1235
Alternative Names: Controlled-release mitochondrial protonophore - OrsoBio; TLC-1235Latest Information Update: 21 Nov 2022
At a glance
- Originator Yale University
- Developer OrsoBio
- Class Nitrophenols; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lipodystrophy; Metabolic disorders
Most Recent Events
- 03 Nov 2022 Pharmacodynamics data from preclinical studies in Lipodystrophy released by OrsoBio (OrsoBio website, November 2022)
- 02 Nov 2022 OrsoBio in-licenses worldwide rights from Yale University to intellectual property of novel mitochondrial protonophores from Yale University
- 02 Nov 2022 OrsoBio receives SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for TLC 1235 in lipodystrophy